Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/a1/a4/06/a1a406bf-4ce9-dac7-a201-03d3b0c19a66/mza_12671109777836408735.jpg/600x600bb.jpg

The Lancet Oncology in conversation with

The Lancet Group

69 episodes

1 day ago

Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care. Click here to read the full Commission: The human crisis in cancer: a Lancet Oncology Commission And comment: Re-establishing human-centred care Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/t...

All content for The Lancet Oncology in conversation with is the property of The Lancet Group and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)

The Lancet Oncology in conversation with

7 minutes

7 months ago

Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)

Professor Amar U. Kishan (Department of Radiation Oncology, University of California, Los Angeles, CA, USA) discusses his paper on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Randomised Trials in the MARCAP Consortium. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00034-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc Tell us what you thought about this episode Continue this conversati...